Development asset linked to Cosmo Pharmaceuticals in public FDA and regional records.
pharma · Chronic Kidney Disease Stage 5 (Dialysis Dependent) · bile acid diarrhoea (BAD)
Cosmo Pharmaceuticals
Cosmo Technologies Ltd
Cosmo Pharmaceuticals drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Dublin, IE HQ
1997 Founded
255 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Dublin, IE
- Founded
- 1997
- Employees
- 255
- Programs
- 3
- Drugs
- 15
- Patents
- 0
Cosmo Pharmaceuticals pipeline
Portfolio lens on 15 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Cosmo Pharmaceuticals drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Cosmo Pharmaceuticals in public FDA and regional records.
-
colesevelam
Cardiovascular system (C10)Cardiovascular system (C10) compound in Cosmo Pharmaceuticals's portfolio.
-
US regulatory status: approved. Molecular target: Bile acids.
- Target
- Bile acids
- Mechanism
- Bile acids sequestering agent
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
Development asset linked to Cosmo Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Cosmo Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Cosmo Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Copper.
- Target
- Copper
- Mechanism
- Copper chelating agent
-
Development asset linked to Cosmo Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA-directed RNA polymerase.
- Target
- DNA-directed RNA polymerase
- Mechanism
- DNA-directed RNA polymerase inhibitor
-
Development asset linked to Cosmo Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Cosmo Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Cosmo Pharmaceuticals in public FDA and regional records.